Trial shows meaningful increase in pregnancy and live birth rates in patients treated with OBE001 ObsEva to proceed with a…
Month: October 2016
ObsEva Announces Plans to Conduct Initial Public Offering in the United States
GENEVA, SWITZERLAND, 17 October, 2016 – ObsEva SA, a Swiss biopharmaceutical company focused on the development and commercialization of novel…
ObsEva Randomizes First Patient in Phase 2b EDELWEISS Study of OBE2109 for the Treatment of Endometriosis
– Clinical trial to assess safety and efficacy of novel GnRH antagonist in patients with pelvic pain associated with endometriosis…